Mark Sapienza

Mark Sapienza

Mark Sapienza, MD

  • Gastroenterology

Languages Spoken

  • Italian
  • Spanish

Specialties, Procedures &
Conditions Treated

Primary Areas of Practice

  • Gastroenterology

Other Areas of Practice

  • Bloodless Medicine
  • Cancer Prevention

Procedures

  • BRAVO pH Monitoring
  • Cancer Screening
  • Capsule Endoscopy
  • Colonoscopy
  • Endoscopy
  • ERCP
  • Fecal Microbiota Transplant
  • Feeding Tube (Percutaneous Endoscopic Gastrostomy; PEG) Placement
  • ORBERA Intragastric Balloon

Conditions Treated

  • Abdominal Hernia
  • Acid Reflux
  • Barrett's Esophagus
  • Celiac Disease
  • Cirrhosis
  • Colitis
  • Colon Cancer
  • Colon Polyps
  • Constipation
  • Crohn's Disease
  • Diarrhea
  • Digestive Diseases
  • Diverticulitis
  • Esophageal Cancer
  • Esophageal Disorders
  • Fatty Liver Disease
  • Gall Stones
  • Gastrointestinal Bleeding
  • GERD (Gastroesophageal Reflux Disease)
  • Heartburn
  • Hemorrhoids
  • Hepatitis
  • Inflammatory Bowel Disease (IBD)
  • Irritable Bowel Syndrome (IBS)
  • Liver Disease
  • Pancreatitis
  • Peptic Ulcer Disease
  • Rectal Bleeding
  • Stomach Cancer
  • Swallowing Disorders
  • Ulcerative Colitis

Locations &
Appointments

Locations

  • Gastroenterology Group of Northern NJ

    420 Grand Ave Englewood, NJ 07631

    Main: 201-569-7044
    Fax: 201-569-1999

About

About Mark Sapienza

Dr. Sapienza is chief of gastroenterology at Englewood Hospital, as well as president of the medical staff. He is board certified in gastroenterology and in internal medicine. He received his MD from Loyola University Chicago Stritch School of Medicine and did his residency, and completed fellowship training in gastroenterology and hepatology,  at Thomas Jefferson University Hospital in Philadelphia.

He is a member of the American Gastroenterological Association, the American College of Gastroenterology, the American Society for Gastrointestinal Endoscopy, and the Crohn's & Colitis Foundation of America. 

Dr. Sapienza practices at the Gastroenterology Group of Northern New Jersey and participates in Englewood Hospital’s bloodless medicine program.

Honors & Awards

  • 2008, 2013, 2016-2019: New Jersey Monthly Magazine Top Doctors
  • 2016, 2018: New York Magazine Top Doctors
  • 2012-2017: 201 Magazine Top Doctors
  • 2016-2018: Inside Jersey Magazine Top Doctors
  • 2016-2018: Castle Connolly Top Doctors
  • 2017, 2018: Bergen Magazine Top Doctors
  • 2015: Englewood Hospital Doctor of the Year

Teaching Positions

  • Clinical Instructor, Mt. Sinai
  • Assistant Professor, Hackensack Meridian School of Medicine at Seton Hall University

Professional Memberships

  • American Gastroenterological Association
  • American Society for Gastrointestinal Endoscopy
  • American College of Gastroenterology
  • Crohn’s & Colitis Foundation

Committees and Leadership Positions

  • President, Englewood Hospital medical staff
  • Section Chief, Gastroenterology
  • 2006, 2007: Former president, New Jersey Gastroenterology and Endoscopy Society
  • 2007-2014: Former President, New Jersey Gastrointestinal PAC (GIPAC)

Education &
Training

Education & Degrees

  • MD: Loyola Stritch School of Medicine 

Residency

  • Thomas Jefferson University Hospital

Fellowship

  • Thomas Jefferson University Hospital, Gastroenterology and Hepatology

Board Certifications

  • Internal Medicine
  • Gastroenterology

Publications

Publications

  • Extraluminal Gastric Carcinoid: Case report of incidentally found extraluminal gastric carcinoid. Published on-line at TJU.
  • Alpha 1-Antitrypsin Deficiency and Liver Disease: Review article. Coauthor. Clinical Perspectives in Gastroenterology. January/February 2002.
  • Treatment of Pyoderma Gangrenosum with Infliximab in Crohn’s DiseaseDigestive Diseases and Sciences. Vol 49, N 9 1454-1457. 2004.
  • Improvement of Pyoderma Gangrenosum after Infliximab Treatment for Fistulizing Crohn’s Disease:Case report involving four female patients with fistulizing Crohn’s disease treated with Infliximab. Published at ACG (#750506). October 2002.
  • A Pilot Study to Assess the Effect of Targeted COX-2 Inhibition on Liver Histology in Patients Infected with Hepatitis C Virus: Study investigated histologic effects of chemoprophylaxis with celexocib in patients infected with HCV over a 6 month period. Published at DDW (T1379). May 2002.